The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an "accelerated approval pathway" that fast-tracks promising clinical treatments for diseases ...
Jan 16, 2023
0
9
US public health officials this week authorized pharmacies to sell abortion pills by prescription. What exactly does that change for women in the United States, after several states banned abortion last year?
Jan 8, 2023
0
3
Europe and North America have seen shortages of the key antibiotic amoxicillin and other medications as surging illnesses particularly among children have increased demand for the drugs.
Dec 20, 2022
0
15
In the competition between brand name pharmaceuticals and their generic counterparts, drug companies use patent gamesmanship to their advantage, one West Virginia University patent expert said.
Dec 19, 2022
0
3
Drug companies must make fundamental changes to their core business to address R&D gaps and access to existing medicines for women's sexual and reproductive health in lower-income countries, global health equity advocates ...
Dec 12, 2022
0
14
Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research.
Dec 2, 2022
0
8
A team of scientists from the National University of Singapore (NUS) has successfully identified the urinary biomarkers of an emerging subclass of synthetic cannabinoids, called OXIZID, to monitor potential abuse. OXIZIDs ...
Nov 30, 2022
0
4
An early surge in cold and flu cases has created shortages in key antiviral and antibiotic drugs needed for the annual "sick season," pharmacists report.
Nov 30, 2022
0
2
Faulty batches of generic lamotrigine tablets—an anti-convulsant drug commonly used for treating bipolar disorder and epilepsy—are being dispensed to patients in Australia. The compromised product is likely a result of ...
Nov 30, 2022
0
25
For years, brand drug companies have been villainized for "evergreening" or manipulating the law to extend the period of exclusivity for drugs beyond their 20-year patent—a practice critics say unfairly prevents competition ...
Nov 3, 2022
0
4
